DIA Makes Key Appointment in China
DIA China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
DIA (Drug Information Association) China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
Dong previously held executive positions as CEO for Lilly China Research and Development Co., a subsidiary of Eli Lilly and Company, and was president and CEO of IMPACT Therapeutics, Inc. He has been employed by Roche in China and the U.S., and by other Chinese and international companies, working in R&D, sales and marketing, business development and executive management.
Dong is a full professor at Nanjing University of Technology, and was named a “Leading Talent in Creativity, Innovation and Entrepreneurship” by the Nanjing New & High Technology Industry Development Zone. He holds an MBA from the China Europe International Business School and a doctorate in chemistry from the University of Washington.
This appointment was prompted by the retirement of Jane Cai, PhD, from the role of DIA China regional director. Under her direction, DIA China was established in 2011 as a legal entity, DIA Beijing Healthcare Information Consulting Ltd. Also, participation of attendees and exhibitors in DIA China Annual Meeting participation doubled, as did membership numbers.
Read the full release here.
Symbravo Outperforms Oral CGRP Inhibitors in Phase III Trial, With Faster, Sustained Migraine Relief
February 24th 2025Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with improved quality of life in patients who previously had an inadequate response to CGRP treatments.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
The Importance of Real-World Evidence in Medical Research and Drug Development
February 18th 2025The ongoing evolution of real-world evidence from a novel concept to a cornerstone of modern medical research signifies its growing importance and vast potential to improve personalized medicine, overall healthcare outcomes, and eventually democratization of scientific facts by general accessibility.
